ストックスクリーナーアプリを入手
2.10
0.48%
0.01
アフターアワーズ：
2.10
前日終値:
$2.09
開ける：
$2.19
24時間の取引高:
8,348
Relative Volume:
1.11
時価総額：
$79.24M
収益：
-
当期純損益:
$-59.51M
株価収益率:
-1.9091
EPS:
-1.1
ネットキャッシュフロー:
$-55.09M
1週間 パフォーマンス:
-21.64%
1か月 パフォーマンス:
-10.99%
6か月 パフォーマンス:
-18.29%
1年 パフォーマンス:
-1.41%
1日の値動き範囲:
$2.10
$2.19
1週間の範囲:
$1.98
$2.58
52週間の値動き範囲:
$1.93
$4.48
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
名前
Armata Pharmaceuticals Inc
セクター
電話
310-655-2928
住所
4503 Glencoe Avenue, Marina del Rey, CA
ARMP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ARMP | 2.10 | 79.24M | 0 | -59.51M | -55.09M | -1.10 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-06-19 | 開始されました | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc (ARMP) 最新ニュース
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - Quantisnow
Armata Pharmaceuticals FY2024 EPS Raised by HC Wainwright - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP) - Defense World
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Armata Pharmaceuticals Reports $3M Revenue, Advances Key Clinical Trials in Q3 | ARMP Stock News - StockTitan
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given "Buy" Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals Announces Structural Biology Publication - PR Newswire
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Decline in Short Interest - MarketBeat
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.2%Should You Sell? - MarketBeat
Armata Pharmaceuticals VP Richard Rychlik Departs with Benefits - TipRanks
10 Best Healthcare Stocks to Invest In (November 2024) - Securities.io
Armata Pharmaceuticals announces executive departure - Investing.com
Arkema S.A. (OTCMKTS:ARKAY) Sees Large Growth in Short Interest - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Confronting Oropouche: a new stage for Cuban science - Radio Cadena Agramonte
Alto Neuroscience's Market Cap Drops To US$358m Leaving Insiders With Losses - Simply Wall St
American Century Companies Inc. Purchases 8,841 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
ANRO’s latest rating updates from top analysts. - Knox Daily
ARKO Corp. (ARKO) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Art’s-Way Manufacturing (NASDAQ:ARTW) Now Covered by StockNews.com - Defense World
Dimensional Fund Advisors LP Has $193.14 Million Position in Archrock, Inc. (NYSE:AROC) - Defense World
Your Safety First: What You Need to Know About Bionpharma’s Urgent Atovaquone Recall - MyChesCo
Building Materials Stocks Q2 Results: Benchmarking Armstrong World (NYSE:AWI) - Yahoo Finance
Aurora Biosynthetics launch set to revolutionise RNA Therapeutics - Manufactures Monthly
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
Atovaquone Oral Suspension Recall Issued Due to Bacterial Contamination Risks - AboutLawsuits.com
Burgundy Asset Management Ltd. Purchases 17,075 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 - GuruFocus.com
New player in RNA manufacturing: Aurora Biosynthetics launches in Australia - Australian Manufacturing
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 11.1% in August - MarketBeat
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Quantisnow
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 133.3% in August - MarketBeat
Armata Pharmaceuticals Updates Progress and Corporate Presentation - TipRanks
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - Longview News-Journal
ARMP Stock Earnings: Armata Pharmaceuticals Beats EPS for Q2 2024 - MSN
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Down 12.9% in July - MarketBeat
Dr. Deborah Birx Is Now The CEO Of Armata Pharmaceuticals - KossyDerrick
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Rating Reiterated by HC Wainwright - Defense World
HC Wainwright Brokers Raise Earnings Estimates for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - Defense World
HC Wainwright Analysts Boost Earnings Estimates for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - MarketBeat
Armata Pharmaceuticals' (ARMP) Buy Rating Reiterated at HC Wainwright - MarketBeat
Armata Pharmaceuticals Welcomes David House as New SVP of Finance - TipRanks
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - Quantisnow
ARMPArmata Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update - StockTitan
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 2.8% - MarketBeat
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
Innoviva’s (INVA) Stock Is Thriving With Strategic Investments Pay-Off - MSN
Armata Pharmaceuticals Inc (ARMP) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):